CD40L-Fc fusion polypeptides and methods of use thereof
US10975155B2 · kind B2 · utility
0Cited by
2References
2Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 12, 2017 |
| Grant date | Apr 13, 2021 |
| Priority date | — |
| Expiry date | Feb 25, 2039 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12P21/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Provided herein is a CD40L-Fc fusion protein and methods of using the fusion protein in the treatment of cancer comprising administering the CD40L-Fc fusion protein or the CD40L-Fc fusion protein in combination with one or more immune checkpoint inhibitors (e.g., an anti-CTLA4 antibody, anti-PD-L1 antibody).
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.